Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
Business Wire•13/10/2026•08:00 ET
0
Key Highlights
- ➤Agilent (A) to acquire Proscia for $240 million cash at closing.
- ➤Proscia deal includes up to $30 million tied to future performance milestones.
- ➤Proscia’s trailing twelve-month revenue exceeds $18 million.
- ➤Proscia serves more than 4,000 laboratories, hospitals, and clinics.
- ➤Transaction expected to close early in Agilent’s fiscal year 2027.
Expert Statements
Padraig McDonnell, President and CEO of Agilent
“Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market”
Padraig McDonnell, President and CEO of Agilent
“The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use. With Proscia’s leading platform and talented team, we will be better equipped to help laboratories and biopharma customers manage and derive insights from pathology data. We look forward to welcoming the Proscia team to Agilent and working together to accelerate adoption of AI-enabled pathology workflows to advance drug discovery and companion-diagnostics solutions and create long-term value for customers and shareholders.”
David West, Co-Founder and CEO of Proscia
“This agreement with Agilent marks an exciting milestone for Proscia and reflects the strength of the platform our team has built.”
David West, Co-Founder and CEO of Proscia
“Agilent shares our vision for advancing pathology through open, digital, and AI-enabled solutions. Together, we can accelerate innovation while continuing to provide customers with the flexibility they need across clinical and life-sciences workflows. I am grateful to the entire Proscia team, whose dedication made this milestone possible, and look forward to building on our work as part of Agilent.”
Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
Advances Agilent’s position as a leading pathology solutions provider, with a unique and differentiated combination of instruments, reagents, and software
Get started
Create a free account to read the full story.